Overview

A Phase I Study Evaluating SCB-313(Recombinant Human TRAIL-Trimer Fusion Protein) for the Treatment of Malignant Pleural Effusion

Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of single dose of SCB-313 by intrapleural injection.To evaluate the safety and tolerability of repeated dose of SCB-313 by intrapleural injection once a day for 3 days, and to determine the maximum tolerated dose (MTD) of SCB-313.
Phase:
Phase 1
Details
Lead Sponsor:
Sichuan Clover Biopharmaceuticals, Inc.